A multicentre analytical comparison study of inter‐reader and inter‐assay agreement of four programmed death‐ligand 1 immunohistochemistry assays for scoring in triple‐negative breast cancer-Reference-Cited by-同舟云学术

A multicentre analytical comparison study of inter‐reader and inter‐assay agreement of four programmed death‐ligand 1 immunohistochemistry assays for scoring in triple‐negative breast cancer

Published:2020-11-27 Issue:4 Volume:78 Page:567-577
ISSN:0309-0167
Container-title:Histopathology
language:en
Short-container-title:Histopathology

Author:

Noske Aurelia¹^ORCID,Ammann Johannes U²^ORCID,Wagner Daniel‐Christoph³,Denkert Carsten⁴,Lebeau Annette⁵⁶,Sinn Peter⁷^ORCID,Kreipe Hans‐Heinrich⁸,Sommer Ulrich⁹,Baretton Gustavo⁹,Steiger Katja¹,Kiechle Marion¹⁰^ORCID,Hieke‐Schulz Stefanie²,Flores Mike¹¹,Roth Wilfried³,Weichert Wilko¹

Affiliation:

1. Technical University of Munich Institute of Pathology MunichGermany

2. Roche Pharma AG Grenzach‐WyhlenGermany

3. Institute of Pathology University Medical Center of the Johannes Gutenberg University Mainz MainzGermany

4. Institute of Pathology Philipps‐University Marburg and University Hospital of Giessen and Marburg MarburgGermany

5. Private Group Practice for Pathology Lübeck LübeckGermany

6. Department of Pathology University Medical Center Hamburg‐Eppendorf HamburgGermany

7. Division of Gynecopathology University Institute of PathologyHeidelberg University Hospital HeidelbergGermany

8. Institute of Pathology Hannover Medical School HannoverGermany

9. Institute of Pathology University Hospital Carl Gustav Carus DresdenTechnical University of Dresden DresdenGermany

10. Department of Gynecology and Obstetrics Klinikum rechts der Isar Technical University of Munich Munich Germany

11. Ventana Medical Systems, Inc. Tucson AZ USA

Publisher

Wiley

Subject

General Medicine,Histology,Pathology and Forensic Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/his.14254

Reference37 articles.

1. Time to disease recurrence in basal-type breast cancers

2. Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer

3. National Comprehensive Cancer Network (NCCN).NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Breast Cancer Version 2 2020. Accessed 21 February 2020. Available at:https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf

4. 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)

5. The screening, diagnosis, treatment, and follow‐up of breast cancer;Wöckel A;Dtsch. Arztebl. Int.,2018

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative analysis of PD-L1 expression and tumor-infiltrating lymphocytes in metaplastic breast carcinoma and gynecologic carcinosarcoma: A single-institution retrospective study;Annals of Diagnostic Pathology;2024-12

2. PD-L1 testing in metastatic triple-negative breast cancer: Interobserver and interplatform reproducibility of CE-IVD assays for CPS and IC scores;Human Pathology;2024-02

3. Advancing the PD-L1 CPS test in metastatic TNBC: Insights from pathologists and findings from a nationwide survey;Critical Reviews in Oncology/Hematology;2023-10

4. Immune Biomarkers in Triple-Negative Breast Cancer: Improving the Predictivity of Current Testing Methods;Journal of Personalized Medicine;2023-07-23

5. Equivalence of laboratory-developed test and PD-L1 IHC 22C3 pharmDx across all combined positive score indications;PLOS ONE;2023-06-02